Risk of thromboembolic events in relation to the management of anticoagulant and antiagregant therapy in patients subjected to endoscopic retrograde cholangiopancreatography.

Autor:	Alejandre-Altamirano RM; Hospital Universitario Reina Sofía, Córdoba, España. Electronic address: h12alalr@gmail.com., Castro-Rodríguez J; Hospital Universitario Reina Sofía, Córdoba, España., Pleguezuelo-Navarro M; Hospital Universitario Reina Sofía, Córdoba, España., Casáis-Juanena LL; Hospital Universitario Reina Sofía, Córdoba, España., Serrano-Ruiz FJ; Hospital Universitario Reina Sofía, Córdoba, España., Martínez-Rodríguez AM; Facultad de Medicina, Universidad de Córdoba, Córdoba, España., Hervás-Molina AJ; Hospital Universitario Reina Sofía, Córdoba, España.
Jazyk:	English; Spanish; Castilian
Zdroj:	Gastroenterologia y hepatologia [Gastroenterol Hepatol] 2023 Feb; Vol. 46 (2), pp. 83-91. Date of Electronic Publication: 2022 Mar 09.
DOI:	10.1016/j.gastrohep.2022.03.001
Abstrakt:	Background and Objectives: The main clinical practice guidelines recommend adequate periprocedural withdrawal and reintroduction of antithrombotic drugs in case of invasive techniques. The main objective of this study was to assess whether, in patients receiving anticoagulant or antiplatelet therapy, the suppression or reduction of the pharmacological dose for the performance of endoscopic retrograde cholangiopancreatography (ERCP) implies a greater risk of thromboembolic events. Patients and Methods: A prospective observational study was carried out, which included 644ERCP performed with therapeutic intention during 2019 at the Reina Sofía University Hospital with follow-up during the 30days after the endoscopic intervention. Results: Six patients presented a thromboembolic event, finding no differences between the incorrect withdrawal/reintroduction of antithrombotic treatment and a higher proportion of thromboembolic or hemorrhagic events after the procedure (P>.05). The incidence of thrombotic events was significantly higher in patients treated with heparin or apixaban (P=.001), as well as with a history of atrial fibrillation (P=.05), rheumatic valve disease (P=.037) and recurrent pulmonary embolism (P=.035), this being also an independent risk factor. Likewise, the incidence of hemorrhage in the 30days post-sphincterotomy was significantly lower in those with implantation of a biliary prosthesis (P=.04). Conclusions: Inadequate periprocedural management of antithrombotic therapy is not associated with a significant increase in the incidence of thromboembolic events in the 30days after ERCP. However, close follow-up and surveillance during the days after this is essential in those patients with a condition that significantly increases the risk of thrombosis. (Copyright © 2022 Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu